Melanoma trials in Greece

In Greece 7 Also abroad 578

7 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
Where
Efkarpia
Age
18 years and over
People
632 worldwide
Run by
mAbxience Research S.L.
See details and how to joinNCT07221734
Phase 1Taking people
A PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo® in participants with resected stage IIB, IIC, or III melanoma in the adjuvant setting
Where
Thessaloniki
Age
18 years and over
People
83 worldwide
Run by
H e x a l AG
See details and how to join2025-521919-39-00 · EU 2025-521919-39-00
Phase 3Taking people
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Where
Athens, Patras
Age
18 years to 70 years
People
670 worldwide
Run by
Iovance Biotherapeutics, Inc.
See details and how to joinNCT05727904 · EU 2022-503140-41-00
Phase 3Taking people
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Where
Athens, Efkarpia
Age
12 years and over
People
400 worldwide
Run by
Replimune, Inc.
See details and how to joinNCT06264180 · EU 2023-508612-29-00
Phase 3Taking people
Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)
Where
Cholargos, Efkarpia
Age
18 years and over
People
119 worldwide
Run by
Mabxience Research S.L.
See details and how to join2025-521562-95-00 · EU 2025-521562-95-00
Phase 3Taking people
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Where
Heraklion, Larissa, Thessaloniki
Age
18 years and over
People
520 worldwide
Run by
IDEAYA Biosciences
See details and how to joinNCT07015190 · EU 2025-522387-32-00
Phase 4Taking people
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
Where
Athens
Age
18 years and over
People
50 worldwide
Run by
Replimune, Inc.
See details and how to joinNCT06887348 · EU 2025-521621-33-00